Lexicon Pharma (LXRX) Tops Q4 EPS by 3c

Lexicon Pharma (NASDAQ: LXRX) reported Q4 EPS of ($0.09), $0.03 better than the analyst estimate of ($0.12). Revenue for the quarter came in at $26.55 million versus the consensus estimate of $7.16 million.

For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.

You May Also Be Interested In

• Four key things investors will watch in Nvidia's earnings next week
• Alpha Tau Medical Ltd. (DRTS) PT Raised to $16 at H.C. Wainwright
• Unicycive Therapeutics, Inc (UNCY) Tops Q2 EPS by 42c